Status:
TERMINATED
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
Detailed Description
Donafenib is a multikinase inhibitor which is acting on various cellular pathways involved in the genesis of acute myeloid leukemia (AML). Donafenib is therefore a promising candidate for improvement ...
Eligibility Criteria
Inclusion
- Patients with diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML) .
- Patients with diagnosed Relapsed AML according to Chinese Guidelines for the Diagnosis and Treatment of Acute Myeloid Leukemia.
- relapse after 6 months of an morphological remission.
- Age ≥ 18 and ≤ 55 years.
- BMI ≥ 18 and ≤27.
- Informed consent, personally signed and dated to participate in the study.
- ECOG performance status of 0-1.
- Life expectancy of at least 12 weeks.
- Total serum bilirubin ≤1.5×ULN.
- Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤ 2.5×ULN.
- Serum creatinine ≤1.5×ULN.
- glomerular filtration rate ≥60 mL/min, as calculated with the Cockcroft-Gault formula.
- alkaline phosphatase ≤1.5×ULN.
- urine protein ≤1+, or Urine protein was quantified for 24h ≤0.5g.
- INR/PTT \<1.5×ULN.
Exclusion
- Patients who are not eligible for standard chemotherapy as per discretion of the treating physician.
- Patients who have been treated with bone marrow transplantation.
- Central nervous system manifestation of AML.
- Cardiac disease: heart failure NYHA III or IV; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
- Patients who have thrombosis events within 6 months prior to study entry is permitted.
- Pregnancy or breastfeed.
- Chronic pulmonary disease with relevant hypoxia.
- Patients undergoing dialysis.
- Known HIV and/or hepatitis C infection.
- Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy.
- Evidence or recent history of CNS disease, including primary or metastatic brain tumors, seizure disorders.
- Blood pressure (BP) higher than systolic 140 mmHg and/or diastolic 90 mmHg after best treatment.
- Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance of the protocol.
- Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entry is permitted.
- Serious, non-healing wound, ulcer or bone fracture.
- Infection need antibiotic treatment.
- Cumulative therapeutic dose of Daunorubicin more than 300mg/m2.
- Concurrent malignancies other than AML.
- History of organ allograft.
- Allergy to study medication or excipients in study medication.
Key Trial Info
Start Date :
November 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04402723
Start Date
November 6 2018
End Date
February 9 2022
Last Update
December 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology and Blood Disease Hospital
Tianjin, Tianjin Municipality, China, 300020